<DOC>
	<DOCNO>NCT00003263</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Interferon alfa may interfere growth cancer cell . Combining chemotherapy , radiation therapy , interferon alfa may kill tumor cell . PURPOSE : Phase I trial study effectiveness cisplatin plus interferon alfa follow surgery interferon alfa plus radiation therapy treat patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Cisplatin , Interferon Alfa , Surgery , Radiation Therapy Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) neoadjuvant interferon alfa 2b ( IFN-A2b ) administer cisplatin patient malignant pleural mesothelioma . II . Determine MTD IFN-A2b administer radiation therapy cisplatin surgery patient . III . Determine response rate toxicity induction therapy IFN-A2b cisplatin patient . IV . Determine toxicity concurrent radiation therapy , cisplatin , IFN-A2b surgery patient . V. Determine local control rate , freedom progression , median survival , long term survival patient combine modality therapy . OUTLINE : This dose escalation study . Patients receive induction therapy consist cisplatin IV weekly interferon alfa 2b ( IFN-A2b ) subcutaneously three time week 6 week . Patients experience least 25 % tumor shrinkage receive another 4 week therapy . Patients undergo debulking surgery remove gross tumor , possible . If resection perform , patient begin radiation therapy 2-6 week surgery . Patients unresectable tumor begin radiation therapy 2-4 week last course induction chemotherapy . Patients undergo radiation therapy 5 day week 6 week . Concurrently , patient receive cisplatin IV weekly IFN-A2b subcutaneously three time week . Cohorts 4 patient receive escalated dos IFN-A2b induction chemotherapy . Once maximum tolerate dose ( MTD ) IFN-A2b establish , one dose level dose use begin dos IFN-A2b adjuvant chemotherapy . If unacceptable toxic effect occur , dose IFN-A2b escalate induction MTD . Patients follow 3-6 week complete radiochemotherapy , every 3 month thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven ipsilateral malignant pleural mesothelioma No contralateral thoracic intraabdominal involvement No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 2,000/mm3 Platelet count great 100,000/mm3 No symptomatic anemia require transfusion Hepatic : Bilirubin le 2.0 mg/dL No autoimmune hepatitis No history decompensated liver disease ; e.g . esophageal varix Ascites Albumin least 2.5 mg/dL Increasing prothrombin time least 2.0 Renal : Creatinine great 1.5 mg/dL Cardiovascular : No symptomatic debilitating cardiovascular disease , No concurrent thrombophlebitic embolic disorder Pulmonary : No symptomatic debilitating pulmonary disease , Pretreatment diffusion capacity great 30 % predict normal Projected posttreatment FEV1 least 1.0 L Other : No prior malignancy within 3 year , except nonmelanomatous skin cancer Carcinoma situ cervix Ductal carcinoma situ breast Not pregnant Fertile patient must use effective contraception No history hypersensitivity interferon component injection No uncontrolled diabetes ( blood sugar consistently least 300 mg/dL ) No insulin dependent diabetes mellitus history ketoacidosis within 1 year No psychosis No uncontrolled thyroid abnormalities No active infection require intravenous antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : No prior debulking surgery No prior chest tube drainage sclerosis tumor resectable Prior thoracentesis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
</DOC>